LivaNova (NASDAQ:LIVN) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Key Points

• LivaNova beat Q1 expectations with $0.98 EPS vs. $0.85 expected and revenue of $362.3M (+14.3% YoY), and raised full‑year 2026 guidance to $4.20–$4.30 EPS with ~7%–8% revenue growth.
• Commercial and clinical catalysts include strong cardiopulmonary momentum (HLM/Essenz adoption and consumables growth), plus regulatory wins—FDA PMA approval of the aura6000 and positive OSPREY RCT data—and a ~48% Medicare reimbursement increase for VNS, though reimbursement and uptake timing remain uncertain.
• Shares jumped ~15% on the news, but the company faces near‑term liquidity pressure with cash down to $540M, Q1 adjusted free cash flow of $4M, and planned full‑year capex of $120M.

LivaNova (NASDAQ:LIVN - Get Free Report) posted its earnings results on Wednesday. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.13, Briefing.com reports. The company had revenue of $362.30 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.LivaNova's quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.88 earnings per share. LivaNova updated its FY 2026 guidance to 4.200-4.300 EPS.

Here are the key takeaways from LivaNova's conference call:

• Company raised full-year 2026 guidance to 7%–8% revenue growth and increased adjusted EPS to $4.20–$4.30, reflecting stronger-than-expected Q1 performance and continued top-line momentum.
• Cardiopulmonary strength: HLM revenue grew in the high teens driven by Essenz upgrade adoption, consumables gained share, and a new manufacturing line (2H26) plus supplier improvements should enable low double-digit output growth and upside to consumables supply.
• Epilepsy tailwinds: U.S. Medicare reimbursement for VNS increased ~48% for new implants (effective Jan 1, 2026) and favorable core VNS study data are improving pricing, reducing discounts, and expected to expand procedure penetration over time.
• Major regulatory and clinical milestones in OSA — FDA PMA approval of the aura6000 and 12‑month OSPREY RCT results (plus PolySync conversion data) materially de‑risk commercialization, but near‑term reimbursement ambiguity and market dynamics leave timing/scale of uptake uncertain.
• Near‑term cash and FCF pressure: cash declined to $540M, adjusted free cash flow was only $4M in Q1 due to higher capital spend and working capital, and full‑year capex is planned at $120M, weighing on short‑term cash conversion.

LivaNova Trading Up 15.1%

Shares of NASDAQ:LIVN traded up $8.67 during trading on Wednesday, reaching $66.26. The stock had a trading volume of 1,932,805 shares, compared to its average volume of 782,619. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29. The stock has a market cap of $3.64 billion, a P/E ratio of -14.86 and a beta of 0.82. The business has a fifty day moving average price of $63.97 and a 200-day moving average price of $62.03. LivaNova has a fifty-two week low of $39.36 and a fifty-two week high of $71.92.

Institutional Trading of LivaNova

Hedge funds and other institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC purchased a new position in shares of LivaNova during the 4th quarter worth $302,000. Pacer Advisors Inc. grew its position in shares of LivaNova by 131.7% in the fourth quarter. Pacer Advisors Inc. now owns 16,661 shares of the company's stock valued at $1,025,000 after purchasing an additional 9,471 shares during the period. Invesco Ltd. increased its stake in LivaNova by 4.5% in the fourth quarter. Invesco Ltd. now owns 1,091,086 shares of the company's stock valued at $67,135,000 after purchasing an additional 47,323 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in LivaNova in the fourth quarter valued at $306,000. Finally, State of Tennessee Department of Treasury lifted its position in LivaNova by 44.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company's stock worth $1,991,000 after buying an additional 9,396 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova News Roundup

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q1 beat consensus on both EPS and revenue — EPS $0.98 vs. $0.85 expected; revenue ~$362.3M, up ~14% year‑over‑year — supporting the rally. LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Company raised FY‑2026 guidance: adjusted EPS guide of 4.20–4.30 (aboveStreet consensus) and revenue guidance roughly $1.4B–$1.5B — this upward revision is the primary driver of positive sentiment. LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
• Positive Sentiment: Analyst/press coverage highlighted the outlook boost, which supported the stock’s gains as investors re‑price the company closer to the improved FY estimate. LivaNova Shares Rise After Outlook Boost
• Neutral Sentiment: Conference-call materials and slides were posted (useful for investors wanting management commentary on growth drivers, reimbursement tailwinds and margin outlook). Listen to Conference Call
• Neutral Sentiment: Trading activity spiked versus the average volume, indicating strong short‑term investor interest but also potential for intra‑day volatility as the market digests the guidance. MarketBeat LIVN Summary
• Negative Sentiment: Some coverage flagged a cautious investor reaction to aspects of the guidance (revenue midpoint vs. some expectations and forward visibility), which led other outlets to report modest share weakness in early trading despite the beat. LivaNova beats estimates but shares fall 2% on guidance concerns LivaNova (LIVN) beats quarterly expectations but shares slip on cautious guidance reaction

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on LIVN shares. Piper Sandler reaffirmed an "overweight" rating and set a $85.00 price target on shares of LivaNova in a research note on Thursday, February 19th. Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a research note on Wednesday, February 25th. Barclays raised their target price on shares of LivaNova from $67.00 to $73.00 and gave the company an "equal weight" rating in a report on Friday, February 27th. Needham & Company LLC lifted their target price on shares of LivaNova from $64.00 to $81.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $66.00 price target on shares of LivaNova in a report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $74.78.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.